Discovering the first microRNA-targeted drug

Research output: Contribution to journal › Journal article › Research › peer-review

Standard

Discovering the first microRNA-targeted drug. / Lindow, Morten; Kauppinen, Sakari.

In: Journal of Cell Biology, Vol. 199, No. 3, 2012, p. 407-412.

Research output: Contribution to journal › Journal article › Research › peer-review

Harvard

Lindow, M & Kauppinen, S 2012, 'Discovering the first microRNA-targeted drug', Journal of Cell Biology, vol. 199, no. 3, pp. 407-412. https://doi.org/10.1083/jcb.201208082

APA

Lindow, M., & Kauppinen, S. (2012). Discovering the first microRNA-targeted drug. Journal of Cell Biology, 199(3), 407-412. https://doi.org/10.1083/jcb.201208082

Vancouver

Lindow M, Kauppinen S. Discovering the first microRNA-targeted drug. Journal of Cell Biology. 2012;199(3):407-412. https://doi.org/10.1083/jcb.201208082

Author

Lindow, Morten ; Kauppinen, Sakari. / Discovering the first microRNA-targeted drug. In: Journal of Cell Biology. 2012 ; Vol. 199, No. 3. pp. 407-412.

Bibtex

@article{884080858aa4454192dec488c53e2552,
title = "Discovering the first microRNA-targeted drug",
abstract = "MicroRNAs (miRNAs) are important post-transcriptional regulators of nearly every biological process in the cell and play key roles in the pathogenesis of human disease. As a result, there are many drug discovery programs that focus on developing miRNA-based therapeutics. The most advanced of these programs targets the liver-expressed miRNA-122 using the locked nucleic acid (LNA){\^a}€“modified antisense oligonucleotide miravirsen. Here, we describe the discovery of miravirsen, which is currently in phase 2 clinical trials for treatment of hepatitis C virus (HCV) infection.",
author = "Morten Lindow and Sakari Kauppinen",
year = "2012",
doi = "10.1083/jcb.201208082",
language = "English",
volume = "199",
pages = "407--412",
journal = "Journal of Cell Biology",
issn = "0021-9525",
publisher = "Rockefeller University Press",
number = "3",

}

RIS

TY - JOUR

T1 - Discovering the first microRNA-targeted drug

AU - Lindow, Morten

AU - Kauppinen, Sakari

PY - 2012

Y1 - 2012

N2 - MicroRNAs (miRNAs) are important post-transcriptional regulators of nearly every biological process in the cell and play key roles in the pathogenesis of human disease. As a result, there are many drug discovery programs that focus on developing miRNA-based therapeutics. The most advanced of these programs targets the liver-expressed miRNA-122 using the locked nucleic acid (LNA)–modified antisense oligonucleotide miravirsen. Here, we describe the discovery of miravirsen, which is currently in phase 2 clinical trials for treatment of hepatitis C virus (HCV) infection.

AB - MicroRNAs (miRNAs) are important post-transcriptional regulators of nearly every biological process in the cell and play key roles in the pathogenesis of human disease. As a result, there are many drug discovery programs that focus on developing miRNA-based therapeutics. The most advanced of these programs targets the liver-expressed miRNA-122 using the locked nucleic acid (LNA)–modified antisense oligonucleotide miravirsen. Here, we describe the discovery of miravirsen, which is currently in phase 2 clinical trials for treatment of hepatitis C virus (HCV) infection.

U2 - 10.1083/jcb.201208082

DO - 10.1083/jcb.201208082

M3 - Journal article

C2 - 23109665

VL - 199

SP - 407

EP - 412

JO - Journal of Cell Biology

JF - Journal of Cell Biology

SN - 0021-9525

IS - 3

ER -

ID: 48996204